1 research outputs found
Preâand postâHSCT use of TKI therapy for fusionâdriven BâALL: A case series of five pediatric, adolescent and young adult patients
Abstract Background The development of tyrosine kinase inhibitors (TKIs) has significantly improved survival rates among patients with Philadelphia chromosome (Ph+) B cell acute lymphoblastic leukemia (BâALL). Phâlike BâALL patients lack the BCR::ABL1 translocation but share gene expression profiles with Ph+âBâALL. The role of TKIs for Phâlike patients preâ and postâhematopoietic stem cell transplantation (HSCT) is not yet clear. Case Here we present five cases of pediatric, adolescent, and young adult patients who presented with Phâlike BâALL or CML in BâALL blast phase who were treated with personalized TKI regimens preâ and postâHSCT. Conclusion This report describes several novel Phâlike fusions as well as combinations of TKIs with chemotherapy or immunotherapy not yet reported in the pediatric population. This case series provides realâworld experience highlighting the potential application of preâ and postâHSCT use of TKIs in a subset of patients with targetable fusions